GlassScriptPhysician profile
David Hal Finkelstein
NPI 1518034628
$21,182.18
in general payments reported to CMS, 2019-2025
34 companies · $3,793 in 2025
The $3,793 reported for 2025 was more than what 88% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,039 · 2020: $3,023 · 2021: $2,186 · 2022: $2,683 · 2023: $3,452 · 2024: $4,006 · 2025: $3,793.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $490.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,761.64 |
| Education | $489.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $2,521.32 | 2019-2025 | Ilumya, Winlevi, Odomzo |
| Abbvie INC. | $2,089.01 | 2019-2025 | |
| Almirall LLC | $1,997.68 | 2019-2025 | Seysara |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $1,894.82 | 2019-2024 | Siliq, Jublia, Arazlo |
| Galderma Laboratories, L.P. | $1,745.56 | 2019-2025 | Nemluvio, Aklief, Epsolay |
| Ucb, INC. | $1,476.01 | 2019-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $1,199.04 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,112.31 | 2022-2025 | Sotyktu |
| Lilly USA, LLC | $1,008.38 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Leo Pharma INC. | $991.66 | 2019-2025 | Adbry, Anzupgo |
| Pfizer INC. | $545.86 | 2019-2025 | |
| Janssen Biotech, INC. | $472.09 | 2020-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $454.22 | 2019-2025 | Dupixent, Libtayo |
| Amgen INC. | $416.90 | 2019-2025 | Otezla, Otezla |
| Incyte Corporation | $411.70 | 2021-2025 | Opzelura |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $369.79 | 2019-2025 | |
| Organon LLC | $363.21 | 2024-2025 | Vtama, Hadlima, Renflexis |
| Arcutis Biotherapeutics, INC. | $336.98 | 2023-2025 | Zoryve |
| Dermavant Sciences, INC. | $323.94 | 2023-2024 | Vtama |
| Genzyme Corporation | $240.97 | 2019-2024 | |
| Celgene Corporation | $206.11 | 2019 | |
| Epi Health, LLC | $182.85 | 2019-2021 | |
| Journey Medical Corporation | $180.29 | 2019-2024 | |
| Vyne Pharmaceuticals INC. | $146.42 | 2020-2021 | |
| Dermira, INC. | $141.43 | 2019-2021 | |
| Sandoz INC. | $82.11 | 2019-2023 | Hyrimoz |
| Sebela Pharmaceuticals INC. | $68.10 | 2019-2021 | |
| Encore Dermatology INC. | $68.09 | 2019-2020 | |
| Botanix Sb INC | $33.34 | 2025 | Sofdra |
| Fresenius Kabi USA, LLC | $29.72 | 2024 | Idacio |
| Aclaris Therapeutics, INC. | $28.86 | 2019 | |
| Mylan Institutional INC. | $16.01 | 2023 | Hulio |
| Promius Pharma LLC | $14.09 | 2019 | |
| Taro Pharmaceuticals USA, INC. | $13.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Finkelstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.